This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Probiotics for antibiotic-associated diarrhea, <i>clostridium difficile</i> infection and irritable bowel syndrome: a review of clinical evidence and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013
A large body of evidence from meta-analyses and randomized controlled trials indicate that compared with placebo, probiotics may reduce the incidence of antibiotic-associated diarrhea and may reduce the severity of symptoms related to irritable bowel syndrome. However, significant heterogeneity and low quality trials require conduct of further well-designed randomized trials that directly compare probiotics. Limited evidence from one meta-analysis suggests treatment with Saccharomyces boulardii in addition to vancomycin or metronidazole may reduce the incidence of recurrent C. difficile infection versus antibiotics alone.
Subject indexing assigned by CRD
Clostridium Infections; Clostridium difficile; Diarrhea; Irritable Bowel Syndrome; Probioticss
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: firstname.lastname@example.org
Date abstract record published